Dermatological manifestations of Down syndrome

Author: Vanessa Ngan, Staff Writer, 2006. Updated by Dr Arun Gangakhedkar, Paediatrician, Waitakere Hospital, Auckland, New Zealand. DermNet NZ Editor in Chief: Adjunct A/Prof Amanda Oakley, Dermatologist, Hamilton, New Zealand. Copy edited by Gus Mitchell/Maria McGivern. October 2018.


Dermatological manifestations of Down syndrome — codes and concepts
open

What is Down syndrome?

Down syndrome is a common genetic disorder resulting from the chromosomal abnormality, trisomy 21. Individuals with Down syndrome have a cognitive delay and characteristic appearances associated with certain medical conditions [1–8].

Who gets Down syndrome?

The incidence of Down syndrome rises with advancing maternal age, but most individuals with Down syndrome are born to younger mothers under 30 years owing to a greater number of pregnancies in this age group. Due to an increase in the terminations of pregnancies with Down syndrome, the live birth prevalence has decreased from one in 700 to about one in 1000 in New Zealand.

Studies suggest marginally higher rates of Down syndrome in boys than girls.

What causes Down syndrome?

A cell division error during early conception results in three copies of chromosome 21 instead of the usual two. The chromosomal abnormality results from nondisjunction (a lack of normal separation) during cell division as the pair of chromosomes in either the sperm or egg fail to separate. This results in a gain of an additional chromosome 21 and the occurrence of Down syndrome [1–8].

  • Standard trisomy 21 is the most common form of Down syndrome (affecting 95% of cases).
  • Translocation Down syndrome also has three copies of chromosome 21, but one of the 21 chromosomes is attached to another chromosome instead of being separate (affecting 3–4% of cases).
  • Mosaic Down syndrome can result from the cell-division error resulting in two populations of cells within the same individual: one group with normal 46 chromosomes and another with trisomy 21 (affecting 1–2% of cases).

The clinical phenotype in all types of Down syndrome is similar, with the subtle differences in mosaic Down syndrome depending on the extent of an individual's trisomy 21 cell population.

What are the clinical features of Down syndrome?

The diagnosis is suspected or confirmed in the neonatal period in most infants with Down syndrome. Characteristic physical features of Down syndrome include [1–8]:

  • Small hands and feet
  • Single transverse palmar crease
  • Associated central hypotonia
  • Congenital heart defects
  • Gastrointestinal malformations
  • Behavioural abnormalities
  • Refractive errors (problems with focusing light accurately onto the retina due to the shape of the eye)
  • Hearing impairment
  • Thyroid dysfunction
  • Distinct facial characteristics
    • Flat facial profile
    • Upward palpebral (inner eyelid) slant
    • Low-set ears
    • Brachycephaly (shortened skull).

Cognitive delay is present in all individuals with Down syndrome. Children are reported to have higher rates of a seizure disorder (8%), coeliac disease, and diabetes (1%).

Red cell macrocytosis and polycythaemia may affect up to two-thirds of infants with Down syndrome. Transient myeloproliferative disorder (TMD), a type of leukaemia resulting from trisomy 21, may be present in up to 10% of newborns. Acute leukaemias are reported in 1 in 300 individuals with Down syndrome.

What are the cutaneous features of Down syndrome?

A single transverse palmar crease is the main cutaneous phenotype and is easily detectable. However, a single transverse palmar crease may also occur as a normal variant that is unilateral in 4% and bilateral in 1% of the general population [9–18].

Other cutaneous features include dry skin and a large tongue with a scrotal appearance.

A variety of dermatological disorders are more common in Down syndrome due to a combination of immune and genetic dysregulation and inefficient physiological processes.

Defective regulation of genes located on chromosome 21 may play a role in keratosis pilarisalopecia areata, and vitiligo. Immune dysregulation leads to increased susceptibility to bacterial and fungal skin infections.

Transient physiological cutaneous manifestations are common during infancy, and chronic skin conditions appear with age.

Cutaneous features of Down syndrome

What are the physiological cutaneous manifestations of Down syndrome?

Acrocyanosis of hands and feet

Acrocyanosis is due to poor peripheral circulation and is more pronounced in Down syndrome. It is commonly observed in newborns.

Cutis marmorata

Cutis marmorata is a lacy, mottled skin discolouration common during early infancy due to altered blood flow in the small blood vessels of the skin. The discolouration is most marked in skin exposed to cooler environmental temperatures.

Livedo reticularis

The skin change due to livedo reticularis is similar but less marked than cutis marmorata. Livedo reticularis mostly affects the lower limbs but may also be present on the arms and trunk. It becomes more pronounced in cold weather.

Premature ageing

The signs of premature ageing reported in Down syndrome include greying or thinning of the hair, skin atrophy, early development of rhytids (wrinkles), and lentigines. The overexpression of the SOD gene, which regulates free radical metabolism, is located on chromosome 21, and is overexpressed as a result of trisomy 21; this leads to excess production of hydrogen peroxide, causing the release of cytotoxic hydroxyl radicals. This, in turn, causes cell-membrane lipid oxidation, altering the structure and function of the skin and involved tissues.

What are the chronic skin manifestations in Down syndrome?

The skin texture is soft and velvety in newborn infants with Down syndrome in comparison to unaffected infants. The skin becomes rough with an altered texture during the school years, with most adolescents and adults showing chronic skin changes [9–18].

Chronic skin conditions associated with Down syndrome may be related to immune insufficiency, autoimmune processes, infections and infestation-related complications, and defects of keratinisation or connective tissue.

Xerosis (dry skin)

The skin in Down syndrome becomes increasingly dry, rough, and inelastic, and there is patchy lichenification with increasing age.

Eczema or atopic dermatitis

Recent studies report a prevalence of atopic eczema of up to 5%, which is similar to the general population. The patches of eczema are red, scaly, and itchy. They generally involve the cheeks, behind the ears, knees, and elbow flexures. Malar erythema is more commonly seen in Down syndrome than in unaffected individuals. Dry skin predisposes individuals to irritant contact dermatitis and allergic contact dermatitis.

Seborrhoeic dermatitis

Seborrhoeic dermatitis occurs in about a third of individuals with Down syndrome, often associated with Malassezia folliculitis. It presents as an erythematous rash with yellow-brown scales involving the scalp, midfacial ‘T’ region, behind the ears, upper chest, and back.

Palmoplantar keratoderma

Palmoplantar keratoderma is thickened skin on the palms and soles and affects up to 40% of those with Down syndrome. Although uncommon in infants under 5 months, the prevalence of palmoplantar keratoderma is up to 75% for children over 5 years with Down syndrome.

Keratosis pilaris

Keratosis pilaris describes rough pinpoint spots (which may contain twisted hair) with varying red–brown pigmentation. The papules affect the upper outer arms, and sometimes the thighs, outer cheeks, trunk, and buttocks, and occasionally the forearms and lower legs. Keratosis pilaris usually appears in adolescence for those with Down syndrome.

Pityriasis rubra pilaris

Pityriasis rubra pilaris (PRP) is a rare chronic papulosquamous disorder of unknown cause. It is characterised by well-defined areas of hyperkeratotic follicular papules that may evolve into erythroderma. PRP causes thick, smooth, yellow palms and soles, and abnormal nails. Immunodeficient states may trigger severe forms of PRP.

Psoriasis

The incidence of psoriasis in the general population is 1–3%; the range is 0.5–8% in people with Down syndrome. Immunocompromised patients may develop severe psoriasis.

Syringoma

Syringomas are benign tumours of the eccrine appendages. They are reported in 18–39% of individuals with Down syndrome (up to 30 times more common than in the general population). They are more commonly found in girls and women. Syringomas often develop during adolescence. They are small (0.5–3 mm) flesh-coloured or yellow–brown dermal papules and are typically distributed in the periorbital area.

Milia-like idiopathic calcinosis

Cutaneous calcinosis may present as asymptomatic discreet, firm, small, chalky-white milia-like papules. These mostly arise on the hands and feet. Their pathogenesis is unclear. Increased sweat calcium and calcification of eccrine ducts may contribute, as there is no preceding injury or calcium metabolism abnormality. The calcinosis heals without scarring. The differential diagnosis includes molluscum contagiosumviral wartsmilia, and inclusion cysts.

Elastosis perforans serpiginosa

Elastosis perforans serpiginosa (EPS) is rare, affecting about 1% of patients with Down syndrome. It presents as asymptomatic, erythematous, and coalescent 2–5 mm keratotic papules arranged in linear, arcuate, or serpiginous patterns. The papules may have umbilicated centres. EPS most commonly appear on the neck but also affects the chin, cheeks, arms, and knees with asymmetrical distribution. The lesions develop slowly during adolescence and spontaneously resolve over 6 months to several years, leaving atrophic linear or retiform scars. Generalised EPS is associated with Down syndrome while the idiopathic form is usually localised. EPS may represent a connective tissue dysplasia with transepidermal elimination of thickened elastic fibres. It is also associated with other connective tissues disorders such as Ehlers–Danlos syndromeMarfan syndromecutis laxapseudoxanthoma elasticum and osteogenesis imperfecta; and it may also be induced by D-penicillamine. The differential diagnosis of EPS includes granuloma annularetinea corporis, annular sarcoidosiscutaneous calcinosis, and porokeratosis of Mibelli.

Elastosis perforans serpiginosa

Anetoderma

Anetoderma is a circumscribed area of flaccid skin, often with fat herniation and a ‘button-hole’ sign on palpation. It most often affects the chest, back, necks, and arms. It is usually secondary to elastolysis, which is induced by leukocytes or bacteria associated with chronic folliculitis. The congenital malformation of elastic fibres in Down syndrome may predispose patients to anetoderma.

Oral lesions

Oral lesions are common in individuals with Down syndrome.

  • Geographic tongue occurs in about 11% of patients with Down syndrome.
  • Up to 40% of individuals with geographic tongue also have a fissured tongue.
  • Fissures and red, scaly skin at the corners of the mouth and lips may also occur (angular cheilitis).
  • Oral bacterial infection and oral candidiasis may occur.
Angular cheilitis in Down syndrome

Vitiligo

Vitiligo presents at any age, with the loss of skin pigmentation anywhere on the body. There is a 3% prevalence of vitiligo in Down syndrome, which is marginally above the 2% prevalence in the general population.

Other pigmentation abnormalities

Other pigmentation abnormalities are common in individuals with Down syndrome.

Alopecia areata

Alopecia areata affects 6–10% of those with Down syndrome compared to the >2% prevalence in the general population.

  • Hair loss can persist, but patchy alopecia regrows in most cases.
  • Alopecia totalis or alopecia universalis affects up to 2.5% of those with Down syndrome.
  • Trichotillomania may coexist in 2–4% of patients with alopecia areata.
  • Alopecia areata is associated with autoimmune conditions such as vitiligohypothyroidism, and trachyonychia.
  • MX1, the alopecia areata gene, is mapped to the distal critical region on chromosome 21. The gene protein MxA is highly expressed in lesional anagen hair bulbs in alopecia areata, but not in normal follicles.
  • Trisomy 21 increases the chance of having the alopecia areata variant gene.

Dermatitis herpetiformis

Dermatitis herpetiformis is rare. It causes a symmetrical, pruritic, 1–3 mm papulovesicular and erosive rash on the extensor aspects of limbs, buttocks, and the midline of the back. Purpuric lesions may be seen on the fingers and toes in children. A coeliac screen should be completed if dermatitis herpetiformis is suspected. Subepidermal bullae with microabscesses in the dermal papillae, with immunoglobulin A deposits on direct immunofluorescence, are confirmatory on skin biopsy.

Hidradenitis suppurativa

Hidradenitis suppurativa causes pustules, nodules, and abscesses in the armpits and groins. The response to treatment with standard antibiotics is often poor.

Hidradenitis suppurativa in Down syndrome

Bacterial infections

A variety of bacterial skin infections affect patients with Down syndrome.

Folliculitis in Down syndrome

Fungal infections

Tinea pedis and onychomycosis are common in Down syndrome.

Dermatophyte infections in Down syndrome

Parasitic infestations

People with Down syndrome are predisposed to scabies infestations. Crusted scabies may occur in Down syndrome and can be asymptomatic and thus diagnosed late, leading to a risk of widespread infestation in the community.

Lichen nitidus

Lichen nitidus causes asymptomatic, flesh-coloured shiny papules (1–2 mm) distributed in crops over the genitalia, abdomen, trunk, and/or upper limbs in children. The histopathology of lichen nitidus reveals focal papillary dermal lymphohistiocytic infiltrates resembling a ‘claw’ or ‘baseball glove and ball’. The strength of the association with Down syndrome is unknown, but several case reports are cited in the medical literature [19].

Acanthosis nigricans

Acanthosis nigricans is a marker of insulin resistance and is associated with obesity. It affects the flexures of the neck, the axilla, and groin. Rarely, it may also affect the flexor aspect of the elbow and knee and the dorsal interphalangeal and metacarpal joints.

Features associated with obesity in Down syndrome

Carotenaemia

Carotenaemia causes a benign yellow–orange hue of the skin involving the nasolabial folds, outer ears, palms, and soles, but sparing the mucous membranes and sclera. It is due to eating excessive carotenoid-containing fruits and vegetables, such as carrots and pumpkin, and has been reported in children on exclusion diets due to food allergy [20]Hypothyroidism associated with Down syndrome may accentuate carotenaemia.

Haematological diseases

Rarely, blood disorders such as a transient myeloproliferative disorder or congenital leukaemia are reported in infants with Down syndrome.

Leukaemia cutis presents as characteristic blue, firm, infiltrated papules or nodular skin lesions.

How is Down syndrome diagnosed?

A clinical diagnosis of Down syndrome is always confirmed by cytogenetic analysis. A standard or conventional karyotype should be requested. A rapid fluorescent in-situ hybridisation (FISH) analysis for trisomy 21 should be specified on the laboratory request form when an urgent result is required.

Post-term, a diagnosis of Down syndrome can be made from the identification of characteristic phenotypic features, but the clinical diagnosis is not always possible in patients with mosaic Down syndrome.

Genetic disorders such as Smith–Magenis syndrome, Zellweger syndrome, and Beckwith–Weidemann syndrome, may be confused for Down syndrome as these syndromes present with similar phenotypic features in early infancy.

A careful skin examination is required as dermatological problems are reported in up to 87% of individuals with Down syndrome [9–18].

  • Clinical surveillance is required for associated conditions such as atlantoaxial instability, obstructive sleep apnoeacoeliac disease, and diabetes.
  • Serum antibody titres and endoscopic biopsy results indicate a higher incidence of coeliac disease in Down syndrome (4.6–7.1%) compared with the general Western population (1–2%).
  • Routine antenatal screening and counselling are offered for high-risk pregnancies.

What is the general management of Down syndrome?

Managing skin and associated medical conditions is important in providing optimal medical care for individuals with Down syndrome.

  • Prenatal screening of the mothers, diagnosis in the early newborn period, regular health surveillance, supervision, and support are all important.
  • Obesity prevention measures are important to avoid skin conditions, musculoskeletal complications, insulin resistance, and diabetes.

Other related support services should include:

  • Educational and community support
  • Genetic counselling services
  • Antenatal screening during pregnancy
  • Chorionic villus biopsy or amniocentesis should be considered in early pregnancy in at-risk mothers (see the DermNet NZ page Prenatal diagnosis of inherited skin conditions), and the pregnancy should be managed with a multidisciplinary team approach.
  • The risk of recurrence in a future pregnancy is slightly higher for the mother with a previous translocation or mosaic Down syndrome.

What is the outcome for patients with dermatological manifestations of Down syndrome?

Most skin conditions may be managed with optimal care and supervision.

Longevity in individuals with Down syndrome is influenced by the severity of their congenital abnormalities and associated medical problems. Substantial improvements in the lifespan are observed with better health surveillance and management compared to a few decades ago.

 

Related information

 

References

  1. Hall B. Mongolism in newborn infants. Clin Pediatr 1966; 5: 4–11. PubMed
  2. Fried K. A score based on eight signs in the diagnosis of Down syndrome in the newborn. J Ment Defic Res 1980; 24: 181–5. PubMed
  3. Hindley D, S Medakkar. Diagnosis of Down’s syndrome in neonates. Arch Dis Child Fetal Neonatal Ed 2002; 87: 220–21. DOI: 10.1136/fn.87.3.F220. PubMed Central
  4. Sivakumar S, Larkins S. Accuracy of clinical diagnosis in Down syndrome. Arch Dis Child 2004; 89: 691–3. DOI: 10.1136/adc.2003.046565. PubMed Central
  5. Hunter AGW. Down syndrome. In: Cassidy SB, Allanson JE (eds). Management of generic syndromes, 3rd edn. Hoboken, NJ: John Wiley & Sons, 2010: 309–36.
  6. Roizen NJ, Patterson D. Down syndrome. Lancet 2003; 361: 1281–9. DOI: 10.1016/S0140-6736(03)12987-X. PubMed
  7. Verma IC, Kabra M, Gangakhedkar AK. Optimal care for Down syndrome in India. Indian J Pediatr. 1996: 63: 121–6. PubMed
  8. NZ Ministry of Health. The clinical assessment and management of children, young people and adults with Down syndrome. Recommended clinical practice. Wellington: Ministry of Health, 2001. Available at: www.health.govt.nz/system/files/documents/publications/downssyndrome.pdf (accessed February 2019).
  9. Kimura M, Cao X, Skurnick J, Cody M, Soteropoulos P, Aviv A. Proliferation dynamics in cultured skin fibroblasts from Down syndrome subjects. Free Radic Biol Med 2005; 39: 374–80. DOI: 10.1016/j.freeradbiomed.2005.03.023. PubMed
  10. Clark SM, Savage L. Dermatological manifestations. In: Newton RW, Puri SC, Marder L (eds). Down syndrome: Current perspectives. London: Mac Keith Press, 2015: 210–28.
  11. Daneshpazhooh M, Nazemi TM, Bigdeloo L, Yoosefi M. Mucocutaneous findings in 100 children with Down syndrome. Pediatr Dermatol 2007; 24: 317–20. DOI: 10.1111/j.1525-1470.2007.00412.x. PubMed
  12. Bilgili SG, Akdeniz N, Karadag AS, Akbayram S, Calka O, Ozkol HU. Mucocutaneous disorders in children with down syndrome: case-controlled study. Genet Couns 2011; 22: 385–92. PubMed
  13. Pozo Cano MD, Gonzàlez Jiménez E, Álvarez Ferre J, Martínez Garcia E, Navarro Jiméneza MC. The skin and its manifestations in the clinical history of children with Down’s syndrome. International Medical Review on Down syndrome 2011; 15: 23–5. DOI: 10.1016/S2171-9748(11)70007-1. Journal
  14. Madan V, Williams J, Lear JT. Dermatological manifestations of Down syndrome. Clin Exp Dermatol 2006; 31: 623–29. DOI: 10.1111/j.1365-2230.2006.02164.x. PubMed
  15. Barankin B, Guenther L. Dermatological manifestations of Down syndrome. J Cutan Med Surg 2001; 5: 289–93. DOI: 10.1177/120347540100500401.PubMed
  16. Schepis C, Barone C, Siragusa M, Pettinato R, Romano C. An updated survey on skin conditions in Down syndrome. Dermatology 2002: 205; 234–8. DOI: 10.1159/000065859. PubMed
  17. Ercis M, Balci S, Atakan N. Dermatological manifestations of 71 Down syndrome children admitted to a clinical genetics unit. Clin Gen 1996; 50: 317–20. PubMed
  18. Pereira AC, Baeta IG, Costa Júnior SR, Gontijo Júnior OM, Vale EC. Elastosis perforans serpiginosa in a patient with Down’s syndrome. An Bras Dermatol 2010; 85: 691–4. PubMed
  19. Botelho LF, Magalhães JP, Ogawa MM, Enokihara MM, Cestari Sda C. Generalized Lichen nitidus associated with Down's syndrome: case report. An Bras Dermatol 2012; 87: 466–8. PubMed
  20. Gangakhedkar A, Somerville R, Jelleyman T. Carotenemia and hepatomegaly in an atopic child on an exclusion diet for a food allergy. Australas J Dermatol 2017; 58: 42–4. DOI: 10.1111/ajd.12414. PubMed

On DermNet NZ

Other websites

Books about skin diseases

See the DermNet NZ bookstore.